Pharmafile Logo

chronic lymphocytic leukaemia

- PMLiVE

BeOne Medicines, BeOne Care Foundation and The Max Foundation renew partnership

This is to expand access to leukaemia treatment in low- and middle-income countries

- PMLiVE

NICE recommends treatments for mantle cell lymphoma and chronic lymphocytic leukaemia

The treatments are for eligible adults in England and Wales

- PMLiVE

BeOne Medicines appoints Kandeepan Ganeshalingam as Vice-President, Head of Medical Affairs, Europe

Ganeshalingam previously held senior leadership roles at Pfizer, Seagen, MSD and Roche

- PMLiVE

Eli Lilly shares positive results for Jaypirca in head-to-head CLL/SLL study

Around 23,690 cases of chronic lymphocytic leukaemia are expected to be diagnosed in the US this year

EU flag

CHMP recommends BeOne Medicines’ Tevimbra for new lung cancer indication

Non-small cell lung cancer accounts for up to 90% of all lung cancer cases

- PMLiVE

NICE recommends BeOne’s Brukinsa to treat mantle cell lymphoma on NHS

Approximately 600 people are affected by the form of non-Hodgkin lymphoma every year in the UK

EU flag

EC approves BeOne Medicines’ Tevimbra to treat nasopharyngeal cancer

The form of head and neck cancer accounted for around 133,000 new global cancer cases in 2020

EU flag

CHMP recommends tablet formulation of BeOne’s targeted cancer drug Brukinsa

The new formulation would allow blood cancer patients to halve their daily pill intake

- PMLiVE

FDA approves tablet formulation of BeOne’s targeted cancer drug Brukinsa

The new formulation has been authorised for all five indications covered by the original capsule version

- PMLiVE

AstraZeneca’s Calquence approved by EC for first-line chronic lymphocytic leukaemia use

An estimated 27,000 cases of the disease were diagnosed in the UK, France, Germany, Spain and Italy in 2024

- PMLiVE

AstraZeneca’s Calquence combination shows promise in chronic lymphocytic leukaemia

Approximately 4,000 new cases of the disease are diagnosed in the UK every year

- PMLiVE

Janssen/Pharmacyclics’ ibrutinib shows continued survival benefit in chronic lymphocytic leukaemia

The slow-growing blood cancer affects approximately 4.92 per 100,000 people every year in Europe

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links